Advertisement

Evaluation of Hepatitis B Vaccine

  • S. Krugman
Conference paper

Abstract

The development of rapid methods to identify the etiology of various infectious diseases is an important objective. However, in the development and evaluation of vaccines, caution and prudence rather than rapidity are essential. The acceleration of vaccine development by so-called “crash programs” can prove to be disastrous.

References

  1. Barker LF, Chisari FV, McGrath PP, et al. (1973) Transmission of type B viral hepatitis to chimpanzees. J Infect Dis 127:648–662PubMedCrossRefGoogle Scholar
  2. Blumberg BS, Alter HJ, Visnich S (1965) A “new” antigen in leukemia sera. JAMA 191:541–546PubMedCrossRefGoogle Scholar
  3. Dane DS, Cameron CH, Briggs M (1970) Virus-like particles in serum of patients with Australia antigen-associated hepatitis. Lancet 1:695–698PubMedCrossRefGoogle Scholar
  4. Francis DP, Hadler SC, Thompson SE, et al. (1982) The prevention of hepatitis B with vaccine. Ann Intern Med 97:362–366PubMedGoogle Scholar
  5. Gallo RC, Salahuddin SZ, Popovic M, et al. (1984) Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:550–552CrossRefGoogle Scholar
  6. Hilleman MR, Buynak EB, Roehm RR, et al. (1975) Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 270:401–403PubMedCrossRefGoogle Scholar
  7. Krugman S, Giles JP, Hammond J (1971) Viral hepatitis, type B (Ms-2 strain): studies on active immunization. JAMA 217:41–45PubMedCrossRefGoogle Scholar
  8. Maupas P, Goudeau A, Coursaget P, et al. (1976) Immunization against hepatitis B in man. Lancet 1:1367–1370PubMedCrossRefGoogle Scholar
  9. Prince AM (1968) An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci USA 60:814–821PubMedCrossRefGoogle Scholar
  10. Purcell RH, Gerin JL (1975) Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpansees. Am J Med Sci 270:395–399PubMedCrossRefGoogle Scholar
  11. Reesink HW, Brummelhnis EH, van Elven LJT, et al. (1978) The preparation and evaluation of a hepatitis B vaccine in the Netherlands. In: Vyas GN, Cohen SN, Schmidt R (eds) Franklin Institute, Philadelphia, p 714Google Scholar
  12. Szmuness W, Stevens CE, Harley EJ, et al. (1980) Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 303:833–841PubMedCrossRefGoogle Scholar
  13. United States Public Health Service Centers for Disease Control (1982) Hepatitis B vaccine safety: report of an inter-agency group. MMWR 31:465–467Google Scholar
  14. United States Public Health Service Centers for Disease Control (1983) The safety of hepatitis B vaccine. MMWR 32:134–136Google Scholar
  15. Vilmer E, Barre-Sinoussi F, Rouzioux C, et al. (1984) Isolation of new lymphotropic retrovirus from two siblings with hemophilia B, one with AIDS. Lancet 1:753–757PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • S. Krugman
    • 1
  1. 1.New York University Medical CenterNew YorkUSA

Personalised recommendations